title: Effects of hyperacute blood pressure and heart rate on stroke outcomes after intravenous tissue plasminogen activator.
abstract: OBJECTIVE
  The present study clarifies associations between stroke outcomes after intravenous tissue plasminogen activator (tPA) and blood pressure (BP) as well as heart rate (HR) profiles.
  
  
  METHODS
  We assessed 125 patients with stroke who received tPA within 3 h of onset. We obtained baseline, mean, maximum, minimum, and coefficient of variation values for BP and HR during the initial 24 h. The primary outcome was independence at 3 months corresponding to a modified Rankin Scale score of 2 or less. The secondary outcomes were early neurological improvement at 24 h and intracerebral hemorrhage (ICH) within 36 h.
  
  
  RESULTS
  Among the patients, 64 (51%) achieved independence, 66 (53%) early improvement, and 26 (21%) developed ICH. The 24-h time courses of SBP (P = 0.033), pulse pressure (PP, P = 0.007), and HR (P < 0.001) were lower among patients who reached independence than among those who did not. After multivariate adjustment, 24-h mean levels of SBP (odds ratio 0.69, 95% confidence interval 0.48-0.97, per 10-mmHg increase), PP (0.63, 0.41-0.94), and HR (0.59, 0.42-0.80, per 10-bpm increase) were inversely associated with independence, as were their maximum and minimum values. In particular, mean SBP values were inversely associated with independence at 8-16 and 16-24 h (0.73, 0.54-0.97 and 0.66, 0.47-0.91, respectively), but not at 0-8 h (0.79, 0.57-1.07). Baseline and maximum SBP were inversely associated with early improvement. Maximum and coefficient of variation of SBP were associated with ICH.
  
  
  CONCLUSIONS
  Lower SBP, PP, and HR values during the initial 24 h after tPA, especially at 8 h thereafter, were associated with independence at 3 months.
authors.affiliation: Department of Cerebrovascular Medicine bDivision of Stroke Care Unit cDepartment of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan. toyoda@hsp.ncvc.go.jp
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Tomii
authors.forename: Kazunori
authors.initials: K
authors.lastname: Toyoda
authors.forename: Takahiro
authors.initials: T
authors.lastname: Nakashima
authors.forename: Tomohisa
authors.initials: T
authors.lastname: Nezu
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Koga
authors.forename: Chiaki
authors.initials: C
authors.lastname: Yokota
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Nagatsuka
authors.forename: Kazuo
authors.initials: K
authors.lastname: Minematsu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001794:Blood Pressure; D005260:Female; D006339:Heart Rate; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D007262:Infusions, Intravenous; D008297:Male; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D010959:Tissue Plasminogen Activator